Review outlines diagnosis and management of non-nutritional rickets

What the study found: Non-nutritional rickets is described as a heterogeneous group of inherited and acquired disorders that cause defective bone mineralization independent of dietary vitamin D or calcium deficiency. The review covers the main subtypes, including several hypophosphatemic rickets forms, tumor-induced osteomalacia, vitamin D-dependent rickets types 1 and 2, and hypophosphatasia.
Why the authors say this matters: The authors conclude that diagnostic algorithms and comparison tables may help clinicians identify these disorders sooner and treat them more individually. They also state that this approach aims to improve long-term musculoskeletal and quality-of-life outcomes in affected children.
What the researchers tested: This is a narrative review that synthesizes current evidence on pathophysiology, clinical presentation, biochemical and radiological diagnosis, and management of principal non-nutritional rickets subtypes. It also highlights burosumab, an anti-fibroblast growth factor 23 monoclonal antibody, asfotase alfa, an enzyme replacement therapy, and emerging molecular therapies.
What worked and what didn't: The abstract states that burosumab and asfotase alfa have a transformative role in management. It does not compare these treatments directly or report which approaches worked best across all subtypes.
What to keep in mind: The available summary does not give detailed study limitations. Because this is a narrative review, the content is a synthesis of current evidence rather than a single new clinical trial.

Key points

• Non-nutritional rickets is a mixed group of inherited and acquired disorders, not caused by vitamin D or calcium deficiency.
• The review covers major subtypes such as hypophosphatemic rickets, tumor-induced osteomalacia, vitamin D-dependent rickets, and hypophosphatasia.
• The authors say diagnostic algorithms and comparison tables may help with earlier identification and individualized treatment.
• Burosumab and asfotase alfa are described as having a transformative role in management.
• The abstract does not report detailed limitations or direct comparisons across treatments.